These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 20851815

  • 1. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
    Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, Lázaro E, de Abajo FJ, Campos J, Spanish ESBL-EARS-Net Study Group.
    J Antimicrob Chemother; 2010 Nov; 65(11):2459-63. PubMed ID: 20851815
    [Abstract] [Full Text] [Related]

  • 2. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martínez-Ruiz R, Pérez-Vázquez M, Alcaraz M, García-Cobos S, Campos J.
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A.
    Arch Intern Med; 2008 Sep 22; 168(17):1897-902. PubMed ID: 18809817
    [Abstract] [Full Text] [Related]

  • 5. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T, Ozyurt M, Baylan O, Bektöre B, Ardiç N, Ceylan S, Erdemoğlu A, Haznedaroğlu T.
    Mikrobiyol Bul; 2009 Oct 22; 43(4):645-9. PubMed ID: 20084918
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W, Li B, Song J, Hong Y, Zhang X, Liu H, Lu H, Zhou T, Cao J.
    Int J Antimicrob Agents; 2017 Jul 22; 50(1):29-34. PubMed ID: 28456703
    [Abstract] [Full Text] [Related]

  • 7. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J.
    Clin Microbiol Infect; 2008 Jan 22; 14 Suppl 1():198-202. PubMed ID: 18154548
    [Abstract] [Full Text] [Related]

  • 8. CTX-M type extended spectrum beta-lactamases in Escherichia coli isolates from community acquired upper urinary tract infections at a university in the European part of Turkey.
    Celik AD, Yulugkural Z, Kuloglu F, Eroglu C, Torol S, Vahaboğlu H, Akata F.
    J Microbiol Immunol Infect; 2010 Apr 22; 43(2):163-7. PubMed ID: 20457435
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS, Suh JY, Peck KR, Lee MY, Oh WS, Kwon KT, Jung DS, Lee NY, Song JH.
    Diagn Microbiol Infect Dis; 2007 May 22; 58(1):111-5. PubMed ID: 17300900
    [Abstract] [Full Text] [Related]

  • 10. Clonal dissemination of highly virulent extended-spectrum beta-lactamase-producing Escherichia coli strains isolated from the urine of non-hospitalised patients in Zagreb region.
    Vranes J, Marijan T, Bedenic B, Mlinaric-Dzepina A, Katic S, Kalenic S.
    Int J Antimicrob Agents; 2008 Feb 22; 31 Suppl 1():S19-24. PubMed ID: 17936594
    [Abstract] [Full Text] [Related]

  • 11. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Wilson DT, May DB.
    Am J Ther; 2013 Feb 22; 20(6):685-90. PubMed ID: 21768870
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
    Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, Senger SS.
    Clin Microbiol Infect; 2010 Feb 22; 16(2):147-51. PubMed ID: 19689464
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
    Rodríguez-Avial C, Rodríguez-Avial I, Hernández E, Picazo JJ.
    Rev Esp Quimioter; 2013 Mar 22; 26(1):43-6. PubMed ID: 23546462
    [Abstract] [Full Text] [Related]

  • 16. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals.
    Peirano G, Costello M, Pitout JD.
    Int J Antimicrob Agents; 2010 Jul 22; 36(1):19-23. PubMed ID: 20359869
    [Abstract] [Full Text] [Related]

  • 17. Fosfomycin susceptibility among extended-spectrum-beta-lactamase-producing Escherichia coli in Nottingham, UK.
    Chislett RJ, White G, Hills T, Turner DP.
    J Antimicrob Chemother; 2010 May 22; 65(5):1076-7. PubMed ID: 20181572
    [No Abstract] [Full Text] [Related]

  • 18. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15.
    Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP.
    J Antimicrob Chemother; 2008 Aug 22; 62(2):284-8. PubMed ID: 18453527
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H, Azap OK, Ergönül O, Timurkaynak F, Urinary Tract Infection Study Group.
    J Antimicrob Chemother; 2005 Nov 22; 56(5):914-8. PubMed ID: 16174685
    [Abstract] [Full Text] [Related]

  • 20. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
    Hernández MS, García JA, Muñoz JL.
    Rev Esp Quimioter; 2009 Mar 22; 22(1):25-9. PubMed ID: 19308743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.